LUCD
Lucid Diagnostics Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.43
+5.03%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.41
From 52W high−70.59%
Volume4.99M
Market cap$82.55M
P/E (TTM)—
P/S (TTM)15.2x
Div yield—
Key dataOct 29, 2026
Open
$0.41
From 52W high
−70.59%
Volume
4.99M
Market cap
$82.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
38.7
MomentumView details →
1D Return
+5.03%
YTD Return
−59.63%
SummaryUpdated Jun 1, 2026
Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage medical diagnostics technology company founded in 2018 and based in New York, New York. The company operates as a subsidiary of PAVmed Inc. and went public in October 2021. Lucid Diagnostics specializes in developing and commercializing diagnostic solutions for patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, particularly the highly lethal esophageal adenocarcinoma. The company has transitioned from early development to commercial operations, processing thousands of tests annually through its proprietary diagnostic platform.
Similar companies
Latest newsMore news →
NASDAQ, INC. notified Lucid Diagnostics Inc. that it was not in compliance with NASDAQ, INC. Listing Rule 5550(a)(2) because of its share price, giving the company until April 12, 2027, to regain compliance.14d agoLucid Diagnostics Inc. reported a Q2 2026 loss of $0.06 per share, missing the Zacks Consensus Estimate of a $0.04 loss and improving from a $0.10 loss a year earlier.78d ago